NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone for preventing ischemic strokes in patients with acute noncardioembolic ...

Odatroltide demonstrated potential in reperfusion-ineligible AIS patients, who currently face significant unmet medical needs.

The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...

A stroke is a life-changing event for patients and a major public health burden. The findings from OCEANIC-STROKE are a notable research achievement, demonstrating a substantial reduction in the risk ...

WILLOWBROOK, Ill., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Pharmazz, Inc. today announced the presentation of positive interim results from its ongoing Phase IV clinical study of sovateltide (Tycamzzi®) in ...

Mobile stroke units (MSU) enable rapid identification and treatment of thrombolytic-eligible patients with acute ischemic stroke (AIS). Recent studies have highlighted the benefit of MSUs over ...

Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...

DAPT also now preferred over lytics for minor nondisabling strokes within 4.5 hours ...

Background: Recurrent stroke burden exceeds 10% within the first year. Dual antiplatelet therapy (DAPT) is recommended for short-term secondary prevention after non-cardioembolic high-risk TIA or ...

Introduction: Post-stroke cognitive impairment (PSCI) is common and often under-recognized, particularly in the acute phase. Most cognitive screening tools provide only a global score, overlooking ...